Of the tracked stories, 5 of 8 also mention Pfizer, the most common co-covered peer. regulation accounts for 5 of the 8 tracked stories, while 2 other categories carry the remainder. They are less corroborated than the beat average, carrying 2.1 original sources each against 3.7 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about GSK
Of the tracked stories, 5 of 8 also mention Pfizer, the most common co-covered peer. regulation accounts for 5 of the 8 tracked stories, while 2 other categories carry the remainder. They are less corroborated than the beat average, carrying 2.1 original sources each against 3.7 for the same window. Negative sentiment reaches 38% here, compared with 25% across the 906-story beat baseline for the same window. The 160-day window averages about 0.4 stories each week. The busiest single day carried 2. Their average consequence score of 6.4 runs above the beat's 6.1 for that window. GSK appears in 8 tracked Healthcare stories published from February 26, 2026 through August 4, 2026.
Stories tracked
8
Per week
0.4
Negative
38%
Sources per story
2.1
Computed from the 8 stories linked to this entity, with beat comparisons drawn from all 906 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering GSK. Shared-story counts are live from our verified record — not editorial picks.
Wave Life Sciences' WVE-007, a novel siRNA silencing Activin E, demonstrated a 16.5% improvement in visceral fat-to-muscle ratio in Phase I, outpacing existing therapies and offering a potential solution for the 70% of GLP-1 users who discontinue within a year. With enrollment underway in the INLIGHT Phase IIa trial, the 175 million individuals with obesity in the U.S. and Europe may soon have a longer-lasting, disease-modifying option.
A potential $400 billion merger between AstraZeneca and Bristol Myers Squibb could reshape oncology competition, with implications for drug costs, patient access, and payer negotiations. The combined portfolio would dominate key cancer markets.
A large-scale public health initiative has launched to vaccinate 5,000 university students against meningitis, addressing a critical risk demographic in communal living environments. The rollout marks a significant push by health authorities to prevent outbreaks during the peak academic season.
Health authorities are mobilizing to contain a rapidly escalating meningitis outbreak characterized as 'explosive' and 'unprecedented.' The surge is forcing a massive reallocation of public health resources and a critical review of current vaccination protocols.
Health authorities have confirmed that Meningitis B is the strain responsible for a recent outbreak that has resulted in two fatalities. The identification triggers immediate public health protocols, including targeted vaccination and antibiotic prophylaxis for close contacts to prevent further spread.
A new feasibility study indicates that maternal immunization programs can be successfully integrated into existing antenatal care frameworks, provided systemic gaps are addressed. Key challenges include cold chain logistics, healthcare worker training, and the need for digital tracking systems to monitor neonatal outcomes.
The CDC has issued a series of travel notices for popular international tourist destinations following a spike in polio detections. The move signals a shift in global health security, requiring travelers to verify immunization status and potentially seek adult boosters before departure.
Wave Life Sciences and Collegium Pharmaceutical released their Q4 and full-year 2025 results, highlighting a pivotal year for RNA editing and specialty pain management. Wave's transition toward a commercial-stage biotech is accelerated by its GSK partnership and landmark clinical data in Alpha-1 antitrypsin deficiency.
